News of Note—Dr. Reddy’s and FDA; Divi’s Labs plant cleared; SK Capital completes Perrigo API deal

newspaper
News of note from pharma manufacturing.

> Dr. Reddy’s in a filing said it will ask the FDA to reinspect its formulations plant in Duvvada in 2018. Announcement (PDF)

> India’s Divi’s Laboratories said in a filing with the Bombay Stock Exhange that the FDA has issued an Establishment Inspection Report for its Unit-II in Visakhapatnam, which had earlier received a Form 483 with six observations. Release (PDF)

> SK Capital has completed its $110 million buyout of Perrigo’s API business. Release | FiercePharma article

Webinar

Use Serialization Data to Maximize Performance and Minimize Risks

Wednesday, March 18 | 11am ET / 8am PT

Serialized products generate a wealth of data as they move through the supply chain. What if you could access and analyze this data to gain operational visibility and powerful business insight? It’s time to put your serialization investment to work for you.

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.